Cargando…
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
OBJECTIVES: The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD). METHODS: We prospectively evaluated CD patients enrolled in the large, observational Crohn's Therapy, Resource, Evaluation, and Assessment Tool regist...
Autores principales: | Lichtenstein, Gary R, Feagan, Brian G, Cohen, Russell D, Salzberg, Bruce A, Diamond, Robert H, Price, Samiyeh, Langholff, Wayne, Londhe, Anil, Sandborn, William J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438468/ https://www.ncbi.nlm.nih.gov/pubmed/22890223 http://dx.doi.org/10.1038/ajg.2012.218 |
Ejemplares similares
-
A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015) -
Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015) -
The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017) -
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021) -
Crohn's disease related strictures in cross‐sectional imaging: More than meets the eye?
por: Sleiman, Joseph, et al.
Publicado: (2022)